The global rapid infusers market has relatively less impacted by the COVID-19 pandemic, with a new report by Future Market Insights (FMI) estimating market revenues to grow at 4.5% through 2030. While growing focus on advanced and novel care is driving growth, high cost, combined with concerns about efficacy continue to limit adoption.
Massive transfusion is the practice of transfusing 10 or more RBC products within a period of 24 hours, which has become increasingly mainstream amidst pediatric patients.
It is crucial for time-restrained operations where blood typing cannot be completed. The transfusion of AB plasma and O RBCs through rapid infusers will remain critical in such emergency procedures.
According to the CDC, 2019 saw more than 48 million surgical and non-surgical procedures. This has resulted in a substantial demand for blood, plasma, and crystalloid fluids, many of which require rapid infusers. Similar statistics in other parts of the globe, indicate potential for sustained growth in the near future.
Key Takeaways
- Market revenues will surpass USD 817 million, with anaesthesia, and emergency healthcare applications being the primary driving factors
- Hospitals will remain the leading end users, while ASCs are also likely to reflect steady growth on the back of growing adoption in outpatient medical procedures.
- Trolley mounted offerings continue to witness market preference, owing to portability and ease of use in hospital settings, accounting for ~70% of market share.
- North America followed by Europe, are leading regional markets for rapid infusers, supported by the massive investments into the healthcare sector, and easier access to new hospital and emergency care technologies.
“The global market for rapid infusers is driven by growing number of surgical procedures and high risk of hypothermia and hypovolemia. This product is also widely considered an important intervention in life-threatening ailments such as sepsis. These issues are major influencers in terms of market development through the forecast period,” said a lead analyst from FMI.
Discover more about report analysis with figures and data tables, along with the table of contents. Ask an Analyst- https://www.futuremarketinsights.com/ask-question/rep-gb-6716
Covid-19 Impact on Rapid Infusers Market
The COVID-19 pandemic is expected to marginally impact the rapid infusers market. Demand largely remains stable as rapid infusers are standard equipment in most healthcare facilities for critical care applications. The demand for reusable rapid infusers is likely to fall in favor of single-use alternatives, owing to concerns over viral transmission.
Potential disruptions of raw material and component supplies due to lockdown and trade restrictions are concerns. However, the essential natures of the products, makes the industry largely exempt from government restrictions. Demand is unlikely to change substantially even in the post-pandemic period as applications in urology, gynecology, and ICUs continue unabated.
Who is Winning?
In a new report, Future Market Insights has provided comprehensive details on essential business strategies that find roles in the rapid infusers market. Market leaders in the industry have been emphasizing on the expansion of their portfolios with efforts on product research. Also, strategic acquisitions are gaining ground in the industry.
Contact Sales for Further Assistance in Purchasing this Report- https://www.futuremarketinsights.com/checkout/6716
3M, GE Healthcare Inc., ZOLL Medical Corporation, Stryker Corporation, Teleflex Incorporated, Smith’s Group plc, Soma Technology Inc., Smisson-Cartledge Biomedical, and Becton, Dickinson and Company are some of the key companies operating in the rapid infuser market.
More Insights
The Future Market Insights report has given readers a detailed analysis of the global rapid infusers market, with critical information on historical demand (2015-2019) and for forecast statistics (2020 – 2030). The report also encompasses a detailed analysis in terms of costs, pricing, and other major dynamic factors that influence tech developments and production decisions for rapid infusers in varied healthcare applications.